<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302299</url>
  </required_header>
  <id_info>
    <org_study_id>2U01AA020776-06</org_study_id>
    <nct_id>NCT03302299</nct_id>
  </id_info>
  <brief_title>Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)</brief_title>
  <acronym>ADEPTT</acronym>
  <official_title>URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mbarara University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) will examine the safety
      and tolerability of, and adherence to, 6 months of daily INH (6H) in 300 TB and HIV-infected
      persons (200 drinkers and 100 non-drinkers) in Uganda. The first aim is to evaluate the
      safety and tolerability of 6H overall and by level of alcohol use. The second aim is to
      estimate adherence and compare adherence by level of alcohol use and at 3 and 6 months.
      Self-reported measures of alcohol use will be augmented by phosphatidylethanol (PEth), an
      established biomarker of alcohol use. Objective measures of adherence will include electronic
      pill bottle monitoring and a novel measure of INH exposure, INH concentration in hair. The
      study will actively monitor for hepatotoxicity using the U.S. standard of care for TB
      preventive therapy for heavy drinkers and discontinue if any Grade 3/4 toxicities are
      detected. The investigators will use the safety, tolerability, and adherence results,
      together with the known efficacy and mortality benefit of TB preventive therapy in
      HIV-infected persons in SSA, and an established decision analytic model of TB preventive
      therapy to conduct the third aim: to determine whether the benefits of TB preventive therapy
      outweigh the toxicity risks for HIV-infected drinkers in resource limited settings. The study
      will additionally follow the cohort every 6 months after completing INH to monitor drinking
      and the development of active TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis (TB) is the leading cause of mortality in persons with HIV worldwide, accounting
      for 20-33% of HIV-related deaths, and is a high-priority area of research in HIV/AIDS by the
      NIH. TB preventive therapy decreases both all-cause mortality and active TB in persons with
      HIV by 30-50% above and beyond the benefits of antiretroviral therapy (ART) alone. Based on
      these findings, the World Health Organization (WHO) recommends isoniazid (INH) preventive
      therapy (IPT) for all persons with HIV in resource constrained settings. However, the WHO
      warns against the use of IPT in persons with &quot;regular and heavy alcohol use.&quot; This exclusion
      stems from concern for increased hepatotoxicity in heavy drinkers in settings where liver
      enzymes are not routinely monitored. Heavy drinking in persons with HIV is very common,
      approximately 25%, in sub-Saharan Africa (SSA). Heavy drinking increases the risk for active
      TB at least threefold; thus, HIV-infected alcohol users should be prioritized for TB
      prevention. However, no studies have systematically assessed the safety of TB preventive
      therapy in heavy drinkers with or without HIV infection. It is critical to examine the safety
      and tolerability of TB preventive therapy for HIV-infected drinkers, given the high rates of
      HIV, TB infection, and alcohol comorbidities worldwide. While the risk of toxicity exists,
      the risk of TB disease could outweigh the toxicity harms. Thus, it is also crucial to
      determine whether the mortality benefits outweigh the toxicity risks for this significant
      portion of the HIV-infected population.

      In addition, TB preventive therapy is only effective if taken consistently for the full
      course. Alcohol use is an established risk factor for decreased ART pill taking and active TB
      treatment discontinuation. Whether HIV-infected drinkers on ART can be adherent to TB
      preventive therapy is not known. Therefore it is essential to determine the level of
      adherence to TB preventive therapy by HIV-infected drinkers on ART, thus this study aims to
      examine adherence to TB preventative therapy as well.

      This is a study to examine 6 months of daily INH (6H) among N=300 persons co-infected with
      HIV and TB. The aims of the study are:

      Aim 1: To examine the safety and tolerability of 6H in HIV/TB co-infected drinkers, measured
      by hepatotoxicity and treatment discontinuation rates. The main aim is to estimate safety and
      tolerability overall among drinkers (primary) and by level of drinking (secondary).

      Aim 2: To determine the level of TB preventive therapy adherence overall among drinkers and
      by level of drinking, and at 3 and 6 months. The main goal of this aim is to estimate
      adherence overall among drinkers (primary). Secondarily the investigators will estimate
      adherence by level of drinking (heavy, current but not heavy drinkers, and non-drinkers) and
      compare adherence across drinking levels. The investigators hypothesize that adherence will
      be highest among the non-drinkers.

      Aim 3: To determine whether the benefits of providing TB preventive therapy to HIV-infected
      drinkers in resource-limited settings outweigh the risks compared to no treatment. The
      investigators hypothesize that providing TB preventive therapy will result in longer life
      expectancy and quality-adjusted life expectancy than not providing TB preventive therapy
      (current standard of care).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3/4 hepatotoxicity</measure>
    <time_frame>Hepatotoxicity occurring during the six month course (180 pills) of INH (which may be taken over a maximum of 9 months)</time_frame>
    <description>Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation</measure>
    <time_frame>Treatment discontinuation occuring during the six month course (180 pills) of INH (which may be taken over a maximum of 9 months)</time_frame>
    <description>Lack of tolerability will be defined as any treatment discontinuation prior to completion of the prescribed course (6 months of INH over a maximum period of 9 months) due to side effects or ALT/AST elevations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INH medication adherence by Electronic Medication Monitoring</measure>
    <time_frame>Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)</time_frame>
    <description>EMM adherence will be defined as the number of pill bottle openings (no more than 1 per day counted) divided by the number of prescribed doses over the study period openings (no more than 1 per day counted) divided by the number of prescribed doses over the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported INH medication adherence by visual analog scale</measure>
    <time_frame>Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH</time_frame>
    <description>The visual analog scale (VAS) asks the patient to identify their past month percent adherence on a visual scale that ranges from 0 to 100%. The VAS is administered at 3- and 6-month interviews. The average of the two measures for this outcome will be used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported INH medication adherence by the Self Rating Single Item (SRSI) scale</measure>
    <time_frame>Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH</time_frame>
    <description>The study will administer the Self Rating Single Item (SRSI) adherence scale, which asks participants to rate their ability to take their medications as prescribed over the past month at the 3- and 6-month interview. The lower score of the 2 surveys administered will be used.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>INH concentration in hair</measure>
    <time_frame>Measured at 3- and 6- months after INH initiation</time_frame>
    <description>INH concentration in hair (ng/mg) will be measured at 3- and 6- months during INH therapy. Average concentration will be used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver injury</measure>
    <time_frame>Study screening visit</time_frame>
    <description>ALT or AST elevations (&gt;2x the upper limit of normal) at study screening</description>
  </other_outcome>
  <other_outcome>
    <measure>Latent tuberculosis</measure>
    <time_frame>Study screening visit</time_frame>
    <description>Latent tuberculosis assessed at screening via tuberculin skin testing</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV/AIDS</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Isoniazid &amp; pyridoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300 Mg ORAL TABLET</intervention_name>
    <description>The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.</description>
    <arm_group_label>Isoniazid &amp; pyridoxine</arm_group_label>
    <other_name>INH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine 25 Mg Oral Tablet</intervention_name>
    <description>All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.</description>
    <arm_group_label>Isoniazid &amp; pyridoxine</arm_group_label>
    <other_name>Vitamin B6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years old

          2. Patient of the MRRH ISS Clinic

          3. HIV-infected

          4. Consume alcohol (self-reported consumption in the prior 3 months) (2/3) OR prior year
             non-drinker (1/3)

          5. Live within 2 hours of travel time to the ISS Clinic

          6. Fluent in either Runyankole or English

          7. No ALT/AST elevations (&lt; = 2X ULN) confirmed by testing

          8. On ART for at least 6 months

          9. No history of active TB, TB treatment, or TB preventive therapy

         10. No probable current active TB as determined by symptom screening and followed by chest
             X-ray and Xpert MTB/RIF (if symptomatic)

         11. Positive TST results confirmed by testing

        Exclusion Criteria:

          1. Plans to move out of the catchment area within 6 months

          2. Probable TB via symptom screen and subsequent assessments

          3. History or current or past active TB, TB treatment, or TB preventive therapy

          4. ALT or AST &gt;2x ULN

          5. Pregnant women with TST positive results who have symptoms of active TB and for whom
             active TB cannot be ruled out via chest X-ray
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith A Hahn, PhD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nneka I Emenyonu, DRPH, MPH</last_name>
    <phone>1-415-476-5806</phone>
    <email>Nneka.Emenyonu@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Fatch, MPH</last_name>
    <phone>1-415-476-5813</phone>
    <email>Robin.Fatch@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mbarara University of Science and Technology/Mbarara Regional Referral Hospital</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ngabirano, BASS</last_name>
      <phone>+256 776 418691</phone>
      <email>ngachrissy28@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adah Tumwegamire, BCS</last_name>
      <phone>+256 774 319258</phone>
      <email>T_Adah@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Winnie R Muyindike, MBChB, MMED</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Adong, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/news/notes/2014/global-tuberculosis-report/en/</url>
    <description>Global Tuberculosis Report: World Health Organization; 2014.</description>
  </link>
  <link>
    <url>http://reliefweb.int/report/world/how-aids-changed-everything-mdg6-15-years-15-lessons-hope-aids-response</url>
    <description>How AIDS Changed Everything: 2014 Global Statistics. UNAIDS;2015.</description>
  </link>
  <link>
    <url>http://apps.who.int/iris/bitstream/10665/44472/1/9789241500708_eng.pdf</url>
    <description>Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings.</description>
  </link>
  <link>
    <url>http://www.cdc.gov/tb/publications/ltbi/treatment.htm</url>
    <description>Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Atlanta: Centers for Disease Control and Prevention;2013</description>
  </link>
  <link>
    <url>http://www.who.int/tb/publications/latent-tuberculosis-infection/en/</url>
    <description>Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization</description>
  </link>
  <link>
    <url>http://www.unaids.org/en/regionscountries/countries/uganda</url>
    <description>UNAIDS Country Report, Uganda. 2014</description>
  </link>
  <link>
    <url>http://www.who.int/substance_abuse/publications/global_alcohol_report/en/</url>
    <description>Global Status Report on Alcohol and Health. Geneva: World Health Organization;2014</description>
  </link>
  <link>
    <url>http://www.who.int/tb/publications/global_report/gtbr15_main_text.pdf</url>
    <description>Global Tuberculosis Report 2015. Wolrd Health Organization;2015.</description>
  </link>
  <reference>
    <citation>Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171. doi: 10.1002/14651858.CD000171.pub3. Review.</citation>
    <PMID>20091503</PMID>
  </reference>
  <reference>
    <citation>Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One. 2015 Sep 8;10(9):e0137492. doi: 10.1371/journal.pone.0137492. eCollection 2015.</citation>
    <PMID>26348618</PMID>
  </reference>
  <reference>
    <citation>TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.</citation>
    <PMID>26193126</PMID>
  </reference>
  <reference>
    <citation>Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One. 2015 Nov 9;10(11):e0142290. doi: 10.1371/journal.pone.0142290. eCollection 2015. Review.</citation>
    <PMID>26551023</PMID>
  </reference>
  <reference>
    <citation>Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009 Mar 13;23(5):631-6. doi: 10.1097/QAD.0b013e328327964f.</citation>
    <PMID>19525621</PMID>
  </reference>
  <reference>
    <citation>Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015 May 12;4(2):105-12. doi: 10.5501/wjv.v4.i2.105. Review.</citation>
    <PMID>25964875</PMID>
  </reference>
  <reference>
    <citation>Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet. 2015 Dec 5;386(10010):2344-53. doi: 10.1016/S0140-6736(15)00323-2. Epub 2015 Oct 26. Review. Erratum in: Lancet. 2015 Dec 5;386(10010):2256.</citation>
    <PMID>26515679</PMID>
  </reference>
  <reference>
    <citation>Kader R, Govender R, Seedat S, Koch JR, Parry C. Understanding the Impact of Hazardous and Harmful Use of Alcohol and/or Other Drugs on ARV Adherence and Disease Progression. PLoS One. 2015 May 1;10(5):e0125088. doi: 10.1371/journal.pone.0125088. eCollection 2015.</citation>
    <PMID>25933422</PMID>
  </reference>
  <reference>
    <citation>Wandera B, Tumwesigye NM, Nankabirwa JI, Kambugu AD, Parkes-Ratanshi R, Mafigiri DK, Kapiga S, Sethi AK. Alcohol Consumption among HIV-Infected Persons in a Large Urban HIV Clinic in Kampala Uganda: A Constellation of Harmful Behaviors. PLoS One. 2015 May 11;10(5):e0126236. doi: 10.1371/journal.pone.0126236. eCollection 2015.</citation>
    <PMID>25962171</PMID>
  </reference>
  <reference>
    <citation>Kader R, Seedat S, Govender R, Koch JR, Parry CD. Hazardous and harmful use of alcohol and/or other drugs and health status among South African patients attending HIV clinics. AIDS Behav. 2014 Mar;18(3):525-34. doi: 10.1007/s10461-013-0587-9.</citation>
    <PMID>23921585</PMID>
  </reference>
  <reference>
    <citation>Kekwaletswe CT, Morojele NK. Alcohol use, antiretroviral therapy adherence, and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus. Patient Prefer Adherence. 2014 Mar 31;8:401-13. doi: 10.2147/PPA.S55547. eCollection 2014.</citation>
    <PMID>24729688</PMID>
  </reference>
  <reference>
    <citation>Medley A, Seth P, Pathak S, Howard AA, DeLuca N, Matiko E, Mwinyi A, Katuta F, Sheriff M, Makyao N, Wanjiku L, Ngare C, Bachanas P. Alcohol use and its association with HIV risk behaviors among a cohort of patients attending HIV clinical care in Tanzania, Kenya, and Namibia. AIDS Care. 2014;26(10):1288-97. doi: 10.1080/09540121.2014.911809. Epub 2014 Apr 29.</citation>
    <PMID>24773163</PMID>
  </reference>
  <reference>
    <citation>Soboka M, Tesfaye M, Feyissa GT, Hanlon C. Alcohol use disorders and associated factors among people living with HIV who are attending services in south west Ethiopia. BMC Res Notes. 2014 Nov 24;7:828. doi: 10.1186/1756-0500-7-828.</citation>
    <PMID>25417542</PMID>
  </reference>
  <reference>
    <citation>Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013;2013:828939. doi: 10.1155/2013/828939. Epub 2013 Feb 12.</citation>
    <PMID>23476764</PMID>
  </reference>
  <reference>
    <citation>Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health. 2008 Aug 14;8:289. doi: 10.1186/1471-2458-8-289. Review.</citation>
    <PMID>18702821</PMID>
  </reference>
  <reference>
    <citation>Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, Patra J, Poznyak V, Popova S. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009 Dec 5;9:450. doi: 10.1186/1471-2458-9-450. Review.</citation>
    <PMID>19961618</PMID>
  </reference>
  <reference>
    <citation>Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011 Mar;133:257-66. Review.</citation>
    <PMID>21441678</PMID>
  </reference>
  <reference>
    <citation>Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202. doi: 10.1097/QAI.0b013e3181b18b6e. Review.</citation>
    <PMID>19668086</PMID>
  </reference>
  <reference>
    <citation>Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study. PLoS One. 2013 Dec 13;8(12):e83480. doi: 10.1371/journal.pone.0083480. eCollection 2013.</citation>
    <PMID>24349518</PMID>
  </reference>
  <reference>
    <citation>Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962.</citation>
    <PMID>25404581</PMID>
  </reference>
  <reference>
    <citation>Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.</citation>
    <PMID>21732833</PMID>
  </reference>
  <reference>
    <citation>Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.</citation>
    <PMID>26260821</PMID>
  </reference>
  <reference>
    <citation>Person AK, Sterling TR. Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep. 2012 Sep;9(3):259-66. doi: 10.1007/s11904-012-0120-1. Review.</citation>
    <PMID>22581360</PMID>
  </reference>
  <reference>
    <citation>Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.</citation>
    <PMID>22150035</PMID>
  </reference>
  <reference>
    <citation>Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005 Mar 1;40(5):670-6. Epub 2005 Feb 1.</citation>
    <PMID>15714411</PMID>
  </reference>
  <reference>
    <citation>Hahn JA, Dobkin LM, Mayanja B, Emenyonu NI, Kigozi IM, Shiboski S, Bangsberg DR, Gnann H, Weinmann W, Wurst FM. Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-positive patients in sub-Saharan Africa. Alcohol Clin Exp Res. 2012 May;36(5):854-62. doi: 10.1111/j.1530-0277.2011.01669.x. Epub 2011 Dec 7.</citation>
    <PMID>22150449</PMID>
  </reference>
  <reference>
    <citation>Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882.</citation>
    <PMID>27155191</PMID>
  </reference>
  <reference>
    <citation>Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789-95.</citation>
    <PMID>9738608</PMID>
  </reference>
  <reference>
    <citation>Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis. Int J Public Health. 2010 Jun;55(3):159-66. doi: 10.1007/s00038-009-0095-x. Epub 2009 Dec 1.</citation>
    <PMID>19949966</PMID>
  </reference>
  <reference>
    <citation>Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J. Causal considerations on alcohol and HIV/AIDS--a systematic review. Alcohol Alcohol. 2010 Mar-Apr;45(2):159-66. doi: 10.1093/alcalc/agp091. Epub 2010 Jan 8. Review.</citation>
    <PMID>20061510</PMID>
  </reference>
  <reference>
    <citation>Amoakwa K, Martinson NA, Moulton LH, Barnes GL, Msandiwa R, Chaisson RE. Risk factors for developing active tuberculosis after the treatment of latent tuberculosis in adults infected with human immunodeficiency virus. Open Forum Infect Dis. 2015 Jan 20;2(1):ofu120. doi: 10.1093/ofid/ofu120. eCollection 2015 Jan.</citation>
    <PMID>26034751</PMID>
  </reference>
  <reference>
    <citation>Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Tuberculosis and excess alcohol use in the United States, 1997-2012. Int J Tuberc Lung Dis. 2015 Jan;19(1):111-9. doi: 10.5588/ijtld.14.0516.</citation>
    <PMID>25519800</PMID>
  </reference>
  <reference>
    <citation>Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis. 2015 Aug 26;15:368. doi: 10.1186/s12879-015-1085-7.</citation>
    <PMID>26306511</PMID>
  </reference>
  <reference>
    <citation>Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, Motsamai OI, Kilmarx PH, Wells CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr. 2010 May 1;54(1):71-7. doi: 10.1097/QAI.0b013e3181c3cbf0.</citation>
    <PMID>19934764</PMID>
  </reference>
  <reference>
    <citation>Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. Review.</citation>
    <PMID>17021358</PMID>
  </reference>
  <reference>
    <citation>Comstock GW. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA. 1986 Nov 21;256(19):2729-30.</citation>
    <PMID>3773185</PMID>
  </reference>
  <reference>
    <citation>Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005 Jul;128(1):116-23.</citation>
    <PMID>16002924</PMID>
  </reference>
  <reference>
    <citation>LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003 Aug 15;168(4):443-7. Epub 2003 May 13.</citation>
    <PMID>12746255</PMID>
  </reference>
  <reference>
    <citation>Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med. 2010 Jul 15;182(2):278-85. doi: 10.1164/rccm.200911-1783OC. Epub 2010 Apr 8.</citation>
    <PMID>20378730</PMID>
  </reference>
  <reference>
    <citation>Tedla Z, Nguyen ML, Sibanda T, Nyirenda S, Agizew TB, Girde S, Rose CE, Samandari T. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana. Chest. 2015 May;147(5):1376-1384. doi: 10.1378/chest.14-0215.</citation>
    <PMID>25340318</PMID>
  </reference>
  <reference>
    <citation>Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008 Nov 18;149(10):689-97.</citation>
    <PMID>19017587</PMID>
  </reference>
  <reference>
    <citation>Getahun H, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015 Sep 17;373(12):1179-80. doi: 10.1056/NEJMc1508223.</citation>
    <PMID>26376149</PMID>
  </reference>
  <reference>
    <citation>Parsons JT, Rosof E, Mustanski B. The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. Health Psychol. 2008 Sep;27(5):628-37. doi: 10.1037/a0012664.</citation>
    <PMID>18823189</PMID>
  </reference>
  <reference>
    <citation>Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JF, Justice AC. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005 Jul;29(7):1190-7.</citation>
    <PMID>16046874</PMID>
  </reference>
  <reference>
    <citation>Duraisamy K, Mrithyunjayan S, Ghosh S, Nair SA, Balakrishnan S, Subramoniapillai J, Oeltmann JE, Moonan PK, Kumar AM. Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India. Ann Am Thorac Soc. 2014 Jun;11(5):712-8. doi: 10.1513/AnnalsATS.201312-447OC.</citation>
    <PMID>24735096</PMID>
  </reference>
  <reference>
    <citation>Namuwenge PM, Mukonzo JK, Kiwanuka N, Wanyenze R, Byaruhanga R, Bissell K, Zachariah R. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg. 2012 Feb;106(2):84-9. doi: 10.1016/j.trstmh.2011.10.015. Epub 2011 Dec 10.</citation>
    <PMID>22154974</PMID>
  </reference>
  <reference>
    <citation>Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41.</citation>
    <PMID>18713501</PMID>
  </reference>
  <reference>
    <citation>Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010 Nov;24 Suppl 5:S49-56. doi: 10.1097/01.aids.0000391022.95412.a6.</citation>
    <PMID>21079428</PMID>
  </reference>
  <reference>
    <citation>Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013 Jan;17(1):284-97. doi: 10.1007/s10461-012-0172-7. Review.</citation>
    <PMID>22407465</PMID>
  </reference>
  <reference>
    <citation>Marcellin F, Spire B, Carrieri MP, Roux P. Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Rev Anti Infect Ther. 2013 Mar;11(3):239-50. doi: 10.1586/eri.13.8. Review.</citation>
    <PMID>23458765</PMID>
  </reference>
  <reference>
    <citation>Simoni JM, Huh D, Wang Y, Wilson IB, Reynolds NR, Remien RH, Goggin K, Gross R, Rosen MI, Schneiderman N, Arnsten J, Golin CE, Erlen JA, Bangsberg DR, Liu H. The validity of self-reported medication adherence as an outcome in clinical trials of adherence-promotion interventions: Findings from the MACH14 study. AIDS Behav. 2014 Dec;18(12):2285-90. doi: 10.1007/s10461-014-0905-x.</citation>
    <PMID>25280447</PMID>
  </reference>
  <reference>
    <citation>Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24(11):1448-52. doi: 10.1080/09540121.2012.687816. Epub 2012 Jun 7.</citation>
    <PMID>22670758</PMID>
  </reference>
  <reference>
    <citation>Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.</citation>
    <PMID>25651245</PMID>
  </reference>
  <reference>
    <citation>Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp GB, Huang Y, Greenblatt RM. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011 May;52(10):1267-75. doi: 10.1093/cid/cir131.</citation>
    <PMID>21507924</PMID>
  </reference>
  <reference>
    <citation>Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, Hyman CL, Cohen M, Young M, Huang Y, Greenblatt RM; Women's Interagency HIV Study (WIHS). Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009 Feb 20;23(4):471-8. doi: 10.1097/QAD.0b013e328325a4a9.</citation>
    <PMID>19165084</PMID>
  </reference>
  <reference>
    <citation>Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002 Oct 15;137(8):696-7.</citation>
    <PMID>12379072</PMID>
  </reference>
  <reference>
    <citation>Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. &quot;White coat compliance&quot; limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008 Jul-Aug;9(4):238-46. doi: 10.1310/hct0904-238.</citation>
    <PMID>18753118</PMID>
  </reference>
  <reference>
    <citation>Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract. 2001 Jul-Aug;55(6):353-7.</citation>
    <PMID>11501221</PMID>
  </reference>
  <reference>
    <citation>Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014 Jan 8;9(1):e83736. doi: 10.1371/journal.pone.0083736. eCollection 2014.</citation>
    <PMID>24421901</PMID>
  </reference>
  <reference>
    <citation>van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011 Apr;56(4):333-9. doi: 10.1097/QAI.0b013e31820dc0cc.</citation>
    <PMID>21239995</PMID>
  </reference>
  <reference>
    <citation>Baxi SM, Greenblatt RM, Bacchetti P, Jin C, French AL, Keller MJ, Augenbraun MH, Gange SJ, Liu C, Mack WJ, Gandhi M; Women’s Interagency HIV Study (WIHS). Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. PLoS One. 2015 Jun 8;10(6):e0129100. doi: 10.1371/journal.pone.0129100. eCollection 2015.</citation>
    <PMID>26053176</PMID>
  </reference>
  <reference>
    <citation>Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. AIDS. 2015 Apr 24;29(7):825-30. doi: 10.1097/QAD.0000000000000619. Erratum in: AIDS. 2015 Nov;29(17):2369.</citation>
    <PMID>25985404</PMID>
  </reference>
  <reference>
    <citation>Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen LV, Kurniati N, Kosalaraksa P, Sudjaritruk T, Chokephaibulkit K, Thammajaruk N, Singtoroj T, Teeraananchai S, Horng H, Bacchetti P, Gandhi M, Sohn AH. Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1009-14. doi: 10.1089/AID.2015.0111. Epub 2015 Aug 26.</citation>
    <PMID>26200586</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008 Nov;22(21):3401-9. doi: 10.1002/rcm.3750.</citation>
    <PMID>18837069</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Yang Q, Yoon K, Lei Y, Shi R, Gee W, Lin ET, Greenblatt RM, Gandhi M. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011 Oct;401(6):1923-33. doi: 10.1007/s00216-011-5278-7. Epub 2011 Aug 17.</citation>
    <PMID>21847531</PMID>
  </reference>
  <reference>
    <citation>Hickey MD, Salmen CR, Tessler RA, Omollo D, Bacchetti P, Magerenge R, Mattah B, Salmen MR, Zoughbie D, Fiorella KJ, Geng E, Njoroge B, Jin C, Huang Y, Bukusi EA, Cohen CR, Gandhi M. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):311-5. doi: 10.1097/QAI.0000000000000154. Erratum in: J Acquir Immune Defic Syndr. 2015 May 1;69(1):e42.</citation>
    <PMID>24694932</PMID>
  </reference>
  <reference>
    <citation>Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D; Prevention of Malaria and HIV disease in Tororo (PROMOTE) study. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):578-84. doi: 10.1097/QAI.0b013e31829c48ad.</citation>
    <PMID>24135775</PMID>
  </reference>
  <reference>
    <citation>Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, Haberer JE, Rooney J, Hendrix CW, Anderson PL, Huang Y, Priddy F, Gandhi M. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):13-20. doi: 10.1097/QAI.0000000000000386.</citation>
    <PMID>25296098</PMID>
  </reference>
  <reference>
    <citation>Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS. 2015 Jan 14;29(2):183-91. doi: 10.1097/QAD.0000000000000531.</citation>
    <PMID>25426808</PMID>
  </reference>
  <reference>
    <citation>Hahn JA, Emenyonu NI, Fatch R, Muyindike WR, Kekiibina A, Carrico AW, Woolf-King S, Shiboski S. Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self-report. Addiction. 2016 Feb;111(2):272-9. doi: 10.1111/add.13173. Epub 2015 Nov 5.</citation>
    <PMID>26381193</PMID>
  </reference>
  <reference>
    <citation>Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007 May;25(5):300-4. Spanish.</citation>
    <PMID>17504682</PMID>
  </reference>
  <reference>
    <citation>Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013 Jul 5;(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Review.</citation>
    <PMID>23828580</PMID>
  </reference>
  <reference>
    <citation>Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC; Uganda-Case Western Reserve University Research Collaboration. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001 Nov 9;15(16):2137-47.</citation>
    <PMID>11684933</PMID>
  </reference>
  <reference>
    <citation>Keeler E. Decision analysis. JAMA. 1977 May 30;237(22):2380.</citation>
    <PMID>404441</PMID>
  </reference>
  <reference>
    <citation>Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, Granich R. Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis. 2014 Oct;18(10):1159-65. doi: 10.5588/ijtld.13.0571.</citation>
    <PMID>25216828</PMID>
  </reference>
  <reference>
    <citation>Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001. doi: 10.1371/journal.pone.0036001. Epub 2012 Apr 30.</citation>
    <PMID>22558301</PMID>
  </reference>
  <reference>
    <citation>Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e84-93. doi: 10.1097/QAI.0000000000000783.</citation>
    <PMID>26258564</PMID>
  </reference>
  <reference>
    <citation>Hahn JA, Fatch R, Kabami J, Mayanja B, Emenyonu NI, Martin J, Bangsberg DR. Self-Report of Alcohol Use Increases When Specimens for Alcohol Biomarkers Are Collected in Persons With HIV in Uganda. J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):e63-4. doi: 10.1097/QAI.0b013e318267c0f1.</citation>
    <PMID>23138732</PMID>
  </reference>
  <reference>
    <citation>Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.</citation>
    <PMID>26405286</PMID>
  </reference>
  <reference>
    <citation>Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015 Sep 24;29(15):1987-2002. doi: 10.1097/QAD.0000000000000802. Review.</citation>
    <PMID>26266773</PMID>
  </reference>
  <reference>
    <citation>Eby J, Chapman J, Marukutira T, Anabwani G, Tshume O, Lepodisi O, Dipotso T, Mokete K, Gross R, Lowenthal E. The adherence-outcome relationship is not altered by diary-driven adjustments of microelectronic monitor data. Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1313-20. doi: 10.1002/pds.3887. Epub 2015 Oct 12.</citation>
    <PMID>26456482</PMID>
  </reference>
  <reference>
    <citation>Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S79-87. Review.</citation>
    <PMID>17133207</PMID>
  </reference>
  <reference>
    <citation>Winhusen TM, Kropp F, Lindblad R, Douaihy A, Haynes L, Hodgkins C, Chartier K, Kampman KM, Sharma G, Lewis DF, VanVeldhuisen P, Theobald J, May J, Brigham GS. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry. 2014 Jul;75(7):757-64. doi: 10.4088/JCP.13m08862.</citation>
    <PMID>24911028</PMID>
  </reference>
  <reference>
    <citation>Amico KR, Fisher WA, Cornman DH, Shuper PA, Redding CG, Konkle-Parker DJ, Barta W, Fisher JD. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):455-9.</citation>
    <PMID>16810111</PMID>
  </reference>
  <reference>
    <citation>Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, Simoni JM, Wilson IB, Saag MS, Kitahata MM, Crane HM. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav. 2013 Jan;17(1):307-18. doi: 10.1007/s10461-012-0326-7.</citation>
    <PMID>23108721</PMID>
  </reference>
  <reference>
    <citation>Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008 Jan;12(1):86-94. Epub 2007 Jun 19.</citation>
    <PMID>17577653</PMID>
  </reference>
  <reference>
    <citation>Reid MC, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med. 1999 Aug 9-23;159(15):1681-9. Review.</citation>
    <PMID>10448769</PMID>
  </reference>
  <reference>
    <citation>McGinnis KA, Justice AC, Kraemer KL, Saitz R, Bryant KJ, Fiellin DA. Comparing alcohol screening measures among HIV-infected and -uninfected men. Alcohol Clin Exp Res. 2013 Mar;37(3):435-42. doi: 10.1111/j.1530-0277.2012.01937.x. Epub 2012 Oct 10.</citation>
    <PMID>23050632</PMID>
  </reference>
  <reference>
    <citation>Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of reliability and validity studies. Clin Invest Med. 2007;30(1):33-41. Review.</citation>
    <PMID>17716538</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Helander A, Hansson T. [National harmonization of the alcohol biomarker PEth]. Lakartidningen. 2013 Sep 25-Oct 8;110(39-40):1747-8. Swedish.</citation>
    <PMID>24245431</PMID>
  </reference>
  <reference>
    <citation>Wurst FM, Thon N, Yegles M, Schrück A, Preuss UW, Weinmann W. Ethanol metabolites: their role in the assessment of alcohol intake. Alcohol Clin Exp Res. 2015 Nov;39(11):2060-72. doi: 10.1111/acer.12851. Epub 2015 Sep 7. Review.</citation>
    <PMID>26344403</PMID>
  </reference>
  <reference>
    <citation>Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):247-8.</citation>
    <PMID>17003672</PMID>
  </reference>
  <reference>
    <citation>Maruotti A. A two-part mixed-effects pattern-mixture model to handle zero-inflation and incompleteness in a longitudinal setting. Biom J. 2011 Sep;53(5):716-34. doi: 10.1002/bimj.201000190. Epub 2011 Aug 24.</citation>
    <PMID>21887792</PMID>
  </reference>
  <reference>
    <citation>Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, Wood K, Wilkinson KA, Ottenhoff TH, Wilkinson RJ. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax. 2011 Aug;66(8):669-73. doi: 10.1136/thx.2011.160168. Epub 2011 May 31.</citation>
    <PMID>21632522</PMID>
  </reference>
  <reference>
    <citation>Cox JA, Lukande RL, Nelson AM, Mayanja-Kizza H, Colebunders R, Van Marck E, Manabe YC. An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One. 2012;7(3):e33685. doi: 10.1371/journal.pone.0033685. Epub 2012 Mar 14.</citation>
    <PMID>22432042</PMID>
  </reference>
  <reference>
    <citation>Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007 Jun 19;21(10):1301-8.</citation>
    <PMID>17545706</PMID>
  </reference>
  <reference>
    <citation>Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM. Health state utilities in latent and active tuberculosis. Value Health. 2008 Dec;11(7):1154-61. doi: 10.1111/j.1524-4733.2008.00355.x. Epub 2008 May 16.</citation>
    <PMID>18489493</PMID>
  </reference>
  <reference>
    <citation>Kirenga BJ, Worodria W, Massinga-Loembe M, Nalwoga T, Manabe YC, Kestens L, Colebunders R, Mayanja-Kizza H. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda. Int J Tuberc Lung Dis. 2013 Mar;17(3):336-41. doi: 10.5588/ijtld.12.0298.</citation>
    <PMID>23407223</PMID>
  </reference>
  <reference>
    <citation>Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, Prabhakar R, Datta M. Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis. 2000 Sep;4(9):839-44.</citation>
    <PMID>10985652</PMID>
  </reference>
  <reference>
    <citation>Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, Mugerwa RD, Ellner JJ. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997 Sep 18;337(12):801-8.</citation>
    <PMID>9295239</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. 2000 Oct 28;356(9240):1470-4.</citation>
    <PMID>11081529</PMID>
  </reference>
  <reference>
    <citation>Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni B, Chaisson RE. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015 Feb 15;60(4):639-45. doi: 10.1093/cid/ciu849. Epub 2014 Nov 2.</citation>
    <PMID>25365974</PMID>
  </reference>
  <reference>
    <citation>Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555-64.</citation>
    <PMID>6754120</PMID>
  </reference>
  <reference>
    <citation>Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013 Feb;26(1):17-25. doi: 10.1097/QCO.0b013e32835ba6b1. Review.</citation>
    <PMID>23221765</PMID>
  </reference>
  <reference>
    <citation>Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, Hogg RS, Cooper C. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS. 2011 Mar 27;25(6):851-5. doi: 10.1097/QAD.0b013e32834564e9.</citation>
    <PMID>21330903</PMID>
  </reference>
  <reference>
    <citation>Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7.</citation>
    <PMID>17621240</PMID>
  </reference>
  <reference>
    <citation>Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006 Oct 7;368(9543):1254-9.</citation>
    <PMID>17027731</PMID>
  </reference>
  <reference>
    <citation>Masiira B, Baisley K, Mayanja BN, Kazooba P, Maher D, Kaleebu P. Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda. Glob Health Action. 2014 Jan 15;7:21843. doi: 10.3402/gha.v7.21843. eCollection 2014.</citation>
    <PMID>24433941</PMID>
  </reference>
  <reference>
    <citation>Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS. 2011 Jan 14;25(2):211-20. doi: 10.1097/QAD.0b013e328340fdf8.</citation>
    <PMID>21124202</PMID>
  </reference>
  <reference>
    <citation>Jelsma J, Maclean E, Hughes J, Tinise X, Darder M. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care. 2005 Jul;17(5):579-88.</citation>
    <PMID>16036244</PMID>
  </reference>
  <reference>
    <citation>Friend-du Preez N, Peltzer K. HIV symptoms and health-related quality of life prior to initiation of HAART in a sample of HIV-positive South Africans. AIDS Behav. 2010 Dec;14(6):1437-47. doi: 10.1007/s10461-009-9566-6. Epub 2009 May 13.</citation>
    <PMID>19437112</PMID>
  </reference>
  <reference>
    <citation>Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014 Jan 15;179(2):216-25. doi: 10.1093/aje/kwt246. Epub 2013 Oct 18.</citation>
    <PMID>24142915</PMID>
  </reference>
  <reference>
    <citation>Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013 Oct;13(10):852-8. doi: 10.1016/S1473-3099(13)70187-7. Epub 2013 Aug 16.</citation>
    <PMID>23954450</PMID>
  </reference>
  <reference>
    <citation>Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009 Mar;63(3):376-86. doi: 10.1111/j.1742-1241.2008.01958.x. Review.</citation>
    <PMID>19222624</PMID>
  </reference>
  <reference>
    <citation>Frey HC, Patil SR. Identification and review of sensitivity analysis methods. Risk Anal. 2002 Jun;22(3):553-78. Review.</citation>
    <PMID>12088234</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Hepatotoxicity</keyword>
  <keyword>Phosphatidtylethanol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators will make de-identified data available to investigators with relevant and well-articulated research plans, after the main study analyses have been conducted. No personal identifiers will be shared, and nor identifiers that could be linked back to the original study ID. In addition, some journals require de-identified data to be posted for public access.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

